文献速递肝病消化道肿瘤与早癌

脂肪性肝病患者的血清铁蛋白水平与肝脏相关事件:一项纵向队列研究

Serum Ferritin Levels and Liver-Related Events in Individuals With Steatotic Liver Disease: A Longitudinal Cohort Study.
PubMed 文献 · Aliment Pharmacol Ther · 2024-11-21

该纵向队列纳入17,560例基线无肝脏相关事件的脂肪性肝病成人,中位随访12.3年。高铁蛋白水平组较正常至低水平组的肝脏相关事件多变量校正风险比为3.13(95%CI 1.89-5.18),且在不同脂肪性肝病亚型及FIB-4分层中趋势一致。

要点

  • 高铁蛋白组(男≥300 μg/L,女≥200 μg/L)肝脏相关事件风险是正常至低铁蛋白组的3.13倍(aHR 3.13,95%CI 1.89-5.18)。
  • MASLD亚组aHR 2.69(95%CI 1.55-4.67),MetALD亚组aHR 5.73(95%CI 1.31-25.0)。
  • 按FIB-4分层:≥1.3者aHR 2.38(95%CI 1.34-4.21),<1.3者aHR 3.13(95%CI 1.18-8.29)。

核心结论

  • 血清铁蛋白水平与脂肪性肝病患者发生肝脏相关事件的风险相关。

研究设计与样本

  • 纵向队列研究,纳入17,560例基线无肝脏相关事件的脂肪性肝病成人,其中MASLD 15,744例、MetALD 1103例、隐源性脂肪性肝病713例。
  • 脂肪肝通过超声诊断,肝脏相关事件定义为发生失代偿(腹水、食管胃底静脉曲张出血和肝性脑病)或肝细胞癌。
  • 按铁蛋白水平分为高(男≥300 μg/L,女≥200 μg/L)与正常至低(男<300 μg/L,女<200 μg/L)两组。

主要发现

  • 随访211,425人年(中位12.3年)期间,共发生74例肝脏相关事件,其中MASLD 63例、MetALD 10例、隐源性脂肪性肝病1例。
  • 高铁蛋白组较正常至低铁蛋白组发生肝脏相关事件的多变量校正风险比为3.13(95%CI 1.89-5.18)。
  • MASLD亚组高铁蛋白组较正常至低铁蛋白组aHR 2.69(95%CI 1.55-4.67)。
  • MetALD亚组高铁蛋白组较正常至低铁蛋白组aHR 5.73(95%CI 1.31-25.0)。
  • FIB-4≥1.3者中高铁蛋白组较正常至低铁蛋白组aHR 2.38(95%CI 1.34-4.21),FIB-4<1.3者中aHR 3.13(95%CI 1.18-8.29)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Serum ferritin has been suggested as a potential biomarker associated with disease progression in metabolic dysfunction-associated steatotic liver disease (MASLD). AIMS: We investigated the association between serum ferritin levels and liver-related events (LREs) in individuals with steatotic liver disease (SLD). METHODS: This cohort study included 17,560 adults with SLD (MASLD [n = 15,744], MASLD with increased alcohol intake (MetALD) [n = 1103] and cryptogenic SLD [n = 713]) without LRE at baseline. A steatotic liver was diagnosed using ultrasound, and LRE was defined as the development of decompensation (ascites, variceal bleeding and hepatic encephalopathy) or hepatocellular carcinoma. Participants were categorised into high (≥ 300 μg/L for males, ≥ 200 μg/L for females) or normal to low (< 300 μg/L for males, < 200 μg/L for females) ferritin levels. RESULTS: During 211,425 person-years of follow-up (median: 12.3 years), 74 incident LRE cases were identified, with 63 cases in MASLD, 10 in MetALD and 1 in cryptogenic SLD. The multivariable-adjusted hazard ratio (aHR) for LRE comparing individuals with high and normal-to-low ferritin level was 3.13 (95% confidence interval [CI] 1.89-5.18). Increased risk of LRE in individuals with high serum ferritin level compared to those with normal to low serum ferritin level was consistent across SLD subtypes (aHR 2.69, 95% CI 1.55-4.67 for MASLD; aHR 5.73, 95% CI 1.31-25.0 for MetALD), and SLD severity assessed by Fibrosis-4 (FIB-4) index (aHR 2.38, 95% CI 1.34-4.21 for FIB-4 ≥ 1.3; aHR 3.13, 95% CI 1.18-8.29 for FIB-4 < 1.3). CONCLUSIONS: Serum ferritin levels correlated with the risk of LRE in patients with SLD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Song BG, Goh MJ, Kang W, et al. Serum Ferritin Levels and Liver-Related Events in Individuals With Steatotic Liver Disease: A Longitudinal Cohort Study. Aliment Pharmacol Ther. 2024. PMID: 39573902. doi:10.1111/apt.18402

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。